Associated Risk of Recombinant Activated Factor VIIa Application.

Conclusion: The proof of direct causality of the events in relation to the administration of FVIIa is difficult because the temporal and therapeutic relationships with concomitant vasoconstrictive and procoagulant therapies were not obvious. However, there remains a suspicion that a higher rate of mesenteric infarctions may be provoked by the administration of FVIIa. PMID: 23803235 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23803235?dopt=Abstract

Source: The Heart Surgery Forum - June 1, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Kiessling AH, Nitsch J, Strouhal U, Kornberger A, Zierer A, Moritz A Tags: Heart Surg Forum Source Type: research